Airway mir-155 responses are associated with TH1 cytokine polarization in young children with viral respiratory infections

Maria Arroyo‡, Kyle Salka‡, Elizabeth Chorvinsky1, Xilei Xuchen1, Karima Abutaleb1, Geovanny F. Perez1, Jered Weinstock2, Susana Gaviria1, Maria J. Gutierrez1, Gustavo Nino1,3*

1 Department of Pediatrics, Division of Pediatric Pulmonary and Sleep Medicine, Children’s National Medical Center, George Washington University, Washington, DC, United States of America, 2 Department of Pediatrics, Division of Pediatric Pulmonology, University at Buffalo, The State University of New York, Buffalo, NY, United States of America, 3 Division of Pediatric Allergy and Immunology, Johns Hopkins University, Baltimore, MD, United States of America

‡ These authors share first authorship on this work.
* gnino@childrensnational.org

Abstract

Background
MicroRNAs (miRs) control gene expression and the development of the immune system and antiviral responses. MiR-155 is an evolutionarily-conserved molecule consistently induced during viral infections in different cell systems. Notably, there is still an unresolved paradox for the role of miR-155 during viral respiratory infections. Despite being essential for host antiviral TH1 immunity, miR-155 may also contribute to respiratory disease by enhancing allergic TH2 responses and NFkB-mediated inflammation. The central goal of this study was to define how airway miR-155 production is related to TH1, TH2, and pro-inflammatory cytokine responses during naturally occurring viral respiratory infections in young children.

Methods
Normalized nasal airway levels of miR-155 and nasal protein levels of IFN-γ, TNF-α, IL-1β, IL-13, IL-4 were quantified in young children (<2 years) hospitalized with viral respiratory infections and uninfected controls. These data were linked to individual characteristics and respiratory disease parameters.

Results
A total of 151 subjects were included. Increased miR-155 levels were observed in nasal samples from patients with rhinovirus, RSV and all respiratory viruses analyzed. High miR-155 levels were strongly associated with high IFN-γ production, increased airway TH1 cytokine polarization (IFN-γ/IL-4 ratios) and increased pro-inflammatory responses. High airway miR-155 levels were linked to decreased respiratory disease severity in individuals with high airway TH1 antiviral responses.
Conclusions
The airway secretion of miR-155 during viral respiratory infections in young children is associated with enhanced antiviral immunity (TH1 polarization). Further studies are needed to define additional physiological roles of miR-155 in the respiratory tract of human infants and young children during health and disease.

Introduction
MicroRNAs (miRNAs) are small non-coding RNA molecules that control gene expression and critically regulate the development of the immune system and antiviral responses [1,2]. Notably, one of the most investigated miRNAs in immunology and virology is miR-155 [3–6]. The interest in this molecule was initially motivated by the discovery that miR-155 is the only miRNA substantially induced by the synthetic viral intermediate poly(I:C) or the host antiviral interferon (IFN) response in macrophages [7]. Over the past decade many studies in humans and animal models have confirmed that miR-155 is an evolutionarily-conserved molecule consistently induced during viral infections in different cell systems [7–12]. Moreover, miR-155 has also been reported to have potent antiviral actions including the activation of CD4+ and CD8+ T cell responses [8–10], the inhibition of SOCS1, the negative regulation of JAK/STAT and IFN signaling [13], and the regulation of multiple TLRs including TLR2, TLR3, TLR4, TLR7 and TLR8 [1,2]. As a result, miR-155 has been shown to enhance TH1 antiviral responses against viruses in vivo [8,12].

Studies in human infants conducted by our team [14] and others [15] have identified abundant airway production of miR-155 during naturally occurring infections caused by rhinovirus (RV) or respiratory syncytial virus (RSV). However, there is still an important unresolved paradox for the role of miR-155 during viral respiratory infections. Despite being essential for the generation of host antiviral TH1 immunity [3–12], miR-155 may also contribute to respiratory disease by enhancing allergic TH2 responses [16–19] and NFkB-mediated inflammation in macrophages and other bone marrow-derived immune cells [20–23]. Recent studies have shown that miR-155 knockout (KO) mice have decreased lung inflammation and recover faster from influenza infection [22]. Similarly, cigarette smoke-induced lung inflammation is reduced in miR-155 KO mice and mitigated by anti-miR-155 treatment [23]. Collectively, these data demonstrate that miR-155 has a powerful but unclear role fine-tuning host TH1/TH2 antiviral immunity. Human-based studies are still needed to better understand the protective and/or pathogenic role(s) of miR-155 during viral respiratory infections.

The central goal of this study was to define, for the first time in human infants, how airway miR-155 production is related to TH1, TH2, and pro-inflammatory cytokine responses during naturally occurring viral respiratory infections. Our results provide novel evidence that high miR-155 levels are associated with the presence of strong TH1 cytokine polarization (IFN-γ/IL-4 ratios) as well as increased airway pro-inflammatory responses. These novel data highlight the importance of investigating the secretory responses of miR-155 in the respiratory tract of young children. The latter can have high impact since miR-155 may play a critical regulatory role for both: 1) the generation of protective host antiviral immunity; and 2) the balance of TH1/TH2 inflammatory responses during viral respiratory infections that occur in early life.
Methods

Study population

Young children (≤2 years; n = 140) were recruited during hospitalization due to PCR-confirmed viral respiratory infection at Children's National Health System (CNHS) in Washington, DC. We included age-matched controls without viral respiratory infection (negative viral PCR) recruited during non-respiratory hospitalizations or outpatient/emergency department visits (n = 11). Characteristics of the study subjects are presented in Table 1. All clinical and demographic variables were obtained by reviewing electronic medical records (EMR) at CNHS. The Institutional Review Board (IRB) of CNHS approved the study and granted a waiver of informed consent given that this research involved materials (data, documents, records, or specimens) collected solely for non-research purposes (clinical indications).

Nasal wash collection, viral PCR analysis, and cytokine measurements

Nasal secretions collected at the onset of acute respiratory illnesses for diagnostic purposes were analyzed by a viral multiplex PCR panel for 12 targets (rhinovirus (RV), RSV A, RSV B, Human Metapneumovirus (HMPV), parainfluenza 1–3, influenza A and B, H1N1, H1N3, Adenovirus) (Luminex, TX, USA). Nasal protein levels of IFN-γ, TNF-α, IL-1β, IL-13, and IL-4 were quantified by electrochemiluminescence (MesoScale, MD, USA).

Quantification of nasal airway miR-155 levels

Total RNA was first extracted from the nasal secretions using MirVana miRNA isolation kit (Invitrogen, AM1560), following enrichment procedure for small RNAs as per manufacturer’s protocol. For normalization, we added a spike-in (Cel-mir-39-3p, sequence 5’-UCACCGGGU GUAACACGCUUG-3’, ThermoFisher miRNA mimic, Assay ID# MC10956, cat# 4464066) to the viral nasal wash prior to mirVana mirna isolation protocol. Extracted RNA was then reverse transcribed into cDNA. Quantitative real-time RT-PCR was used to measure miR-155 and Cel-mir-39 levels (TaqMan assay, ThermoFisher, MA, USA). The following primers were used: Cel-mir-39 primer (ThermoFisher MicroRNA assay, Assay ID: 000200) Stem-loop sequence of primer 5’-UAUACCGAGAGCCCAGCUGAUUUCGUCUUGGAUAAUGCUCGUAAU GAGAUUUACCCGGGGUGUUAAUCACGCUUGGCUUGGUUC-3’, HSA-mir-155 primer (ThermoFisher MicroRNA assay, Assay ID: 002623).

Table 1. Nasal airway miR-155 levels according to respiratory viruses in young children.

| Virus          | N  | Nasal miR-155 levels** | p-value*** |
|---------------|----|------------------------|-----------|
| Control       | 11 | 1.33 (0.1–3.8)         | Reference |
| All viruses   | 140| 7.04 (1.6–37.9)        | 0.004     |
| RSV           | 32 | 10.8 (1.4–34)          | 0.008     |
| RV            | 82 | 4.56 (1.3–32.8)        | 0.014     |
| Adenovirus    | 19 | 14.2 (3.4–234)         | 0.004     |
| Parainfluenza | 10 | 3.53 (1.2–21.8)        | 0.14      |
| Influenza     | 10 | 25.3 (3.6–94)          | 0.04      |
| HMPV          | 22 | 5.8 (1.3–39)           | 0.02      |
| Mixed         | 36 | 4.54 (1.7–46.5)        | 0.01      |

https://doi.org/10.1371/journal.pone.0233352.t001
Stem-loop sequence of primer 5’ UUAAUGCUAAUCGUGAUAGGGGUUGUUCUUAUACAAACAGACACCUAACAGGCUAGC-3’

The delta Ct (ΔΔCt) method was used to calculate final miR-155 levels normalized to a spike-in control (cel-mir-39, ThermoFisher, MA, USA).

Clinical and demographic variables

We collected demographic and clinical information from EMR to evaluate disease severity including wheezing, retractions, supplemental O2 needs, respiratory rate, and heart rate at the initial presentation. We combined these parameters into a composite respiratory distress score as described [24] (S1 Table).

Data analysis

Descriptive statistics included Chi-square test for binary variables and non-parametric tests (Wilcoxon test) for continuous variables. Comparisons of miR-155 levels and cytokines across groups were done with Kruskal-Wallis test or Wilcoxon test as appropriate. Linear regression models (univariate and multivariate) were built to examine the association between miR-155 levels and other molecular/clinical predictors with respiratory severity scores at initial presentation. Significance was taken at the P < 0.05 level. (V.19 Minitab, Inc., PA, USA).

Results

Airway production of miR-155 during viral respiratory infection in early life

A total of 151 subjects were included in this study. We found that relative to uninfected controls (n = 11), young children (≤2 years) hospitalized with viral respiratory infection (n = 140) had significantly increased nasal levels of miR-155 (Table 1). No significant differences were observed according to viral pathogen or mixed infections (Table 1). All viruses had increased miR-155 levels relative to controls (uninfected group), although Parainfluenza did not reach statistical significance likely due to the small number of cases (Table 1).

Baseline characteristics of all study subjects are shown in Table 2. Due to the presence of non-parametric distribution and extreme miR-155 values, we used quartiles to define groups of children with low (<25th percentile), medium (25-50th percentile) or high (>75th percentile) airway miR-155 levels. We did not identify significant differences in demographics or baseline clinical characteristics among the individuals with low, medium or high airway miR-155 levels during viral respiratory infections (Table 2).

MiR-155 production is associated with stronger airway TH1 and pro-inflammatory responses in young children with viral respiratory infections

To begin to understand the physiological function of miR-155 in the airways during early life, we examined the nasal cytokine responses of the children with viral respiratory infections (n = 140) according to individual miR-155 levels. As shown in Fig 1, we found that those with the highest miR-155 airway levels (>75th percentile) had significantly higher TH1 antiviral cytokine responses (IFN-γ) and increased production of pro-inflammatory (TNF-α, IL-1β) and TH2 cytokines (IL-4, IL-13). Importantly, we also identified that high miR-155 airway levels were strongly associated with increased TH1 cytokine polarization (IFN-γ/IL-4 ratios, Fig 2 or IFN-γ /IL-13 ratios S1 Fig). The subset of subjects with the highest virus-induced TH1 cytokine polarization (IFN-γ/IL-4 ratios >75th percentile; n = 34) also had significantly higher pro-inflammatory responses (TNF-α, IL-1β levels) and increased normalized miR-155 levels.
Fig 1. Nasal miR-155 levels stratified as high (>75th%ile), medium (25-75th%ile), or low (<25th%ile) demonstrate that young children with high miR-155 levels during viral respiratory infections (green boxplots) have higher airway production of (A) IFN-γ, (C) TNF-α, (C) IL-1β, (D) IL-4 and (E) IL-13.

https://doi.org/10.1371/journal.pone.0233352.g001

Table 2. Baseline characteristics of study subjects: VRI = viral respiratory infection, RSV = human respiratory syncytial virus, RV = human rhinovirus, HMPV = human metapneumovirus. *Percentage of each virus includes single and mixed viral infections. **p values obtained by Kruskal-Wallis test for continuous variables and logistic regression for binary variables (RV reference group for viral pathogens).

| Variable                   | Controls | VRI High miR-155 | VRI Medium miR-155 | VRI Low miR-155 | **p-value |
|----------------------------|----------|------------------|--------------------|-----------------|-----------|
| Total number of subjects, n| 11       | 35               | 70                 | 11              | -         |
| Age in years, median       | 0.81     | 0.99             | 1.13               | 1.11            | 0.36      |
| Male (%)                   | 63       | 60               | 65                 | 60              | 0.94      |
| Black race/ethnicity (%)   | 64       | 46               | 59                 | 66              | 0.77      |
| Preterm (%<37 weeks gestation) | 40 | 31               | 50                 | 48              | 0.18      |

Viral pathogen *

| Viral pathogen | Controls | VRI High miR-155 | VRI Medium miR-155 | VRI Low miR-155 | **p-value |
|----------------|----------|------------------|--------------------|-----------------|-----------|
| RV (%)         | -        | 63               | 60                 | 51              | 0.59      |
| RSV (%)        | -        | 25               | 23                 | 20              | 0.94      |
| HMPV (%)       | -        | 17               | 16                 | 14              | 0.85      |
| Parainfluenza (%) | -  | 9               | 9                  | 3               | 0.52      |
| Influenza (%)  | -        | 3                | 7                  | 11              | 0.77      |
| Adenovirus (%) | -        | 6                | 13                 | 23              | 0.10      |
| Mixed (%)      | -        | 23               | 25                 | 28              | 0.97      |

https://doi.org/10.1371/journal.pone.0233352.t002

(Fig 3). We did not identify a significant difference in IL-13 responses subjects with the highest virus-induced TH1 cytokine polarization (p = 0.08). These data indicate that there is a subset of young children with viral respiratory infections characterized by a distinct airway molecular signature that includes high miR-155 levels and high TH1/pro-inflammatory responses.
Nasal airway miR-155 levels and clinical severity during viral respiratory infections in young children

We also examined the association between nasal airway miR-155 responses and the severity of viral respiratory infections using respiratory distress scores that included wheezing, retractions, supplemental O2 needs, respiratory rate, and heart rate at the initial presentation (S1 Table). Given that miR-155 and pro-inflammatory nasal airway responses (TNF-α, IL-1β) were significantly different in children with high TH1 polarization (IFN-γ:IL-4 ratios >75th percentile, Fig 3), we subdivided our study subjects according to high TH1 vs. non-high TH1 status. Notably, we found that higher nasal miR-155 levels and higher IFN-γ antiviral responses were significantly associated with lower severity scores independently of age and RSV status in the subset of young children with high TH1 polarization (Table 3). However, this association was not present in the rest of the children with viral respiratory infections (IFN-γ:IL-4 ratios ≤75th percentile; n = 106, Table 3). In individuals with high TH1 polarization we also found that higher severity scores were linked to previously identified risk factors for severe viral respiratory infection in young children [24–27] including preterm status (<37 weeks gestation), black race and RSV status adjusted by younger age (Table 3).

Fig 2. Nasal miR-155 levels stratified as high (>75th%ile), medium (25-75th%ile), or low (<25th%ile) demonstrate that young children with high miR-155 levels during viral respiratory infections (green boxplots) have higher airway TH1 cytokine polarization (IFN-γ:IL-4 ratios, calculated with protein concentration pg/ml).

https://doi.org/10.1371/journal.pone.0233352.g002
**Discussion**

This study provides novel human-based molecular insights about the regulation of antiviral airway responses during early life. We identified that miR-155 is increased in the nasal aspirates of young children (<2 years) during viral infections independent of the causative respiratory virus. We also examined for the first time the in vivo correlation of nasal miR-155 levels with pro-inflammatory cytokines (TNF-α, IL-1β) and with the expression of miR-155 relative to control.

![Image](https://doi.org/10.1371/journal.pone.0233352.g003)

Fig 3. Individuals with a high TH1 polarization profile (IFN-γ:IL-4 ratios >75th%tile; red boxplots; n = 34) have a distinct airway molecular signature characterized by higher nasal miR-155 levels and increased nasal protein levels of pro-inflammatory cytokines (TNF-α, IL-1β) relative to the rest of study subjects (IFN-γ:IL-4 ratios ≤75th percentile; yellow boxplots; n = 106). Nasal levels (y axis) correspond to protein concentration (pg/ml) for TNF-α, IL-1β and to normalized expression for miR-155 (ΔΔCt method normalized to a spike in control cel-miR-39).

https://doi.org/10.1371/journal.pone.0233352.g003

### Table 3. Airway miR-155, TH1 responses and clinical severity during viral respiratory infections

| Respiratory severity score | Efffect estimate (β) | p-value | Respiratory severity score | Effect estimate (β) | p-value |
|---------------------------|----------------------|---------|---------------------------|----------------------|---------|
| MiR-155                   | -0.005               | 0.04    | MiR-155                   | 0.002               | 0.47    |
| IFN-γ                     | -0.0004              | 0.02    | IFN-γ                     | -0.0004             | 0.24    |
| IL-1β                     | 0                    | 0.96    | IL-1β                     | -0.0003             | 0.52    |
| TNF-α                     | -0.0007              | 0.54    | TNF-α                     | -0.001              | 0.88    |
| Age                       | -1.31                | 0.15    | Age                       | -0.58               | 0.14    |
| Sex                       | -1.13                | 0.32    | Sex                       | 0.73                | 0.28    |
| Black race                | 3.31                 | 0.002   | Black race                | -0.005              | 0.123   |
| Preterm                   | 3.8                  | 0.001   | Preterm                   | 0.961               | 0.138   |
| RV                        | 0.90                 | 0.44    | RV                        | -1.2                | 0.07    |
| RSV                       | 2.60                 | 0.09    | RSV                       | 0.92                | 0.28    |

*High TH1 group defined as IFN-γ:IL-4 ratios >75th%tile, **Regression model adjusted by age and RSV status.

https://doi.org/10.1371/journal.pone.0233352.t003
responses, individual airway cytokine profiles, and clinical severity during naturally occurring viral respiratory infections in young children. The importance of these data is that miR-155 is an evolutionarily-conserved molecule with essential but still unclear roles promoting both TH1 antiviral immunity [3–12], as well as TH2 allergic inflammation [16–19]. Thus, there is increasing interest in defining the precise role(s) of miR-155 in human airway immunity and in the pathobiology of airway diseases such as COPD [23], asthma [28], and viral respiratory infections in young children [14,15].

Over the past decade many studies have identified that miR-155 is a master regulator of the immune system [1,2]. Indeed, there is strong evidence that miR-155 controls CD8+ and CD4 + T cell activation, proliferation, and cytokine production in vitro and in vivo during viral infection (8–10). MiR-155 also plays a crucial role in the generation of protective adaptive immune responses in B-cells, including antigen presentation and antibody production [3]. Several studies have reported that miR-155 is essential for the generation of TH2-mediated inflammation as well [16–19]. Dendritic cells [16] and type 2 innate lymphoid cells [19] derived from miR-155(-/-) KO mice have limited TH2 priming capacity. Additionally, CD4 + TH2 cells require intrinsic miR-155 expression for type-2 immune polarization [18]. This experimental evidence has led to the notion that miR-155 may be a potential target to alleviate TH2-driven conditions, including allergic asthma [17,28]. Nonetheless, most of this evidence is derived from animal models and the physiological function of miR-155 in the human airways during health and disease is still poorly understood. Filling this void is critically necessary before pursuing miR-155-based clinical applications. Our current study begins to address this gap with new data about the human airway miR-155 responses during viral respiratory infections in early life. Specifically, we identified that high miR-155 levels are associated with increased production of TH1 (IFN-γ) and TH2 cytokines (IL4, IL-13) in the nasal airways of young children with viral respiratory infections. Although miR-155 was linked to smaller changes in IL-4 and IL-13 (Fig 1), it is possible that subtle changes may be biologically relevant for allergic inflammation. Thus, these results are in line with the reported dual role of miR-155 promoting TH1 (antiviral) [3–12] and TH2 (allergic) responses [16–19]. However, in our study we also identified that high miR-155 levels were primarily associated with enhanced TH1 cytokine polarization (greater IFN-γ/IL-4 ratios, Fig 2), indicating that, although miR-155 likely has several effects in the airways, the overall physiological role of miR-155 in human infants and young children appears to be the upregulation of host antiviral immunity during viral respiratory infections.

MiR-155 is also a robust marker of pro-inflammatory responses in different cell systems [20–23]. There is compelling evidence demonstrating that miR-155 is highly expressed in macrophages, dendritic cells, as well as T and B lymphocytes [1–3] and is selectively exported by these cells in exosomes to allow cell-to-cell communication and amplification of pro-inflammatory responses in the lungs [29]. Thus we believe that the association between high miR-155 levels and TH1 cytokine polarization in our study is likely the result of multiple processes during viral infections: 1) the secretion of exosomes containing miR-155 triggered by respiratory viruses [14,29]; 2) the effects of miR-155 promoting pro-inflammatory responses and a TH1 bias [3–12]; and 3) the positive feedback generated by TH1 and other pro-inflammatory cytokines that induce miR-155 production [7,30]. Together, these processes may lead to an autocrine/paracrine loop in the airways to promote TH1 polarization in individuals with high miR-155 levels during viral respiratory infections. Nonetheless, there are alternative explanations for the link between miR-155 and TH1 responses. For instance, given that viral loads were not obtained in this study, it is also possible that the production of miR-155 could have been driven by higher viral replication. Thus the production of miR-155 and IFN-γ (as well as other cytokines) might be similarly upregulated by another factor (such as viral load or timing.
of infection). In addition, it is important to clarify that our findings only pertain to the nasal airway mucosa since respiratory viruses may be acting differently in nasal or bronchial cells inducing miRNA-155.

Our results also suggest that in the setting of a viral respiratory infection, the interplay between miR-155 and TH1 responses may promote additional pro-inflammatory responses in the airways. Specifically, we found that: 1) young children with high miR-155 nasal levels during viral infection had increased production of pro-inflammatory cytokines (TNF-α, IL-1β); and 2) the individuals with the highest levels of TH1 cytokine polarization had higher TNF-α and IL-1β levels. These data indicate that there is a subset of young children with viral respiratory infections characterized by high miR-155 levels and high TH1/pro-inflammatory responses. Notwithstanding the compelling evidence linking miR-155 with pro-inflammatory responses [20–23], it is relevant to note that the mechanisms by which miR-155 controls inflammation are complex and appear to be cell specific due to context-dependent miR-155 targeting and regulation of gene expression [5,6]. Certainly, there is compelling evidence demonstrating that in bone marrow-derived immune cells (e.g. macrophages), miR-155 potentiates NF-κB activity and induces the production of pro-inflammatory cytokines (e.g. TNF-α) via suppression of SHIP1 and SOCS1 (miR-155 targets) [21]. Conversely, studies in endothelial cells have identified that miR-155 can inhibit NF-κB-driven inflammation by targeting RELA (p65/NF-κB) directly [31]. Indeed, RELA contains highly conserved miR-155-binding sites in its 3'-UTR, and experimental evidence (gene reporter assays) has confirmed that miR-155 can bind to these target sites to suppress NF-κB activation in endothelial cells [31]. Other studies have reported additional cytoprotective effects of miR-155 on these cells [32,33]. Thus, we believe that additional studies are needed to examine the actions of miR-155 in a cell specific and context-dependent manner because miR-155 targets and companion functional outcomes may vary across different human airway cell types and in the presence of different immune and inflammatory mediators.

In concert with the above observations, it is noteworthy that in our study the association between clinical severity and miR-155 responses during viral infections was context-dependent and varied according to the individual airway TH1 responses. Specifically, we found that higher miR-155 levels were associated with lower respiratory disease severity in the subset of children with the highest TH1 responses but not in the rest of children (Table 2). In children with high TH1 polarization, we also observed that less clinical severity was linked to a higher production of IFN-γ but not of other cytokines associated high miR-155 levels (TNF-α, IL-1β, Fig 3 and Table 2). Collectively, these findings suggest that the evolutionarily-conserved function of miR-155 in the airways of human infants is primarily to provide host protection by enhancing antiviral immunity during early life (e.g. TH1 responses). Nonetheless, it is possible that the airway production of miR-155 in different contexts (e.g. smoke inhalation) may amplify inflammatory responses and lead to greater respiratory disease severity [23], particularly in individuals prone to develop severe airway inflammatory responses (e.g. asthma or COPD) [23,28].

In conclusion, the present study examined the airway production of miR-155 in young children during in vivo viral respiratory infections. The results provide new evidence that miR-155 is strongly linked to high IFN-γ production and enhanced airway TH1 cytokine polarization (IFN-γ/IL-4 ratios). High airway miR-155 levels were linked to decreased respiratory disease severity in individuals with high TH1 antiviral responses. These observations are consistent with the collection of evidence implicating crucial roles for miR-155 in regulating antiviral airway responses in several animal models and cell systems [3–23]. Our current results demonstrate that miR-155 is also relevant to the immunobiology of the human airways during early life, and they highlight the need to conduct additional studies to better define the physiological
role(s) of the secretory responses of miR-155 in the respiratory tract of human infants and young children.

Supporting information

S1 Fig. Nasal miR-155 levels stratified as high (>75th%ile), medium (25-75th%ile), or low (<25th%ile) demonstrate that young children with high miR-155 levels during viral respiratory infections have higher airway TH1 cytokine polarization (IFN-γ:IL-13ratios).

S1 Table. Respiratory distress score.

Author Contributions

Conceptualization: Maria Arroyo, Kyle Salka, Geovanny F. Perez, Jered Weinstock, Maria J. Gutierrez, Gustavo Nino.

Data curation: Maria Arroyo, Kyle Salka, Elizabeth Chorvinsky, Xilei Xuchen, Karima Abutaleb, Maria J. Gutierrez, Gustavo Nino.

Formal analysis: Maria Arroyo, Kyle Salka, Gustavo Nino.

Funding acquisition: Kyle Salka, Maria J. Gutierrez, Gustavo Nino.

Investigation: Maria Arroyo, Kyle Salka, Elizabeth Chorvinsky, Xilei Xuchen, Karima Abutaleb, Geovanny F. Perez, Jered Weinstock, Susana Gaviria, Maria J. Gutierrez, Gustavo Nino.

Methodology: Maria Arroyo, Kyle Salka, Elizabeth Chorvinsky, Xilei Xuchen, Karima Abutaleb, Geovanny F. Perez, Jered Weinstock, Susana Gaviria, Gustavo Nino.

Project administration: Xilei Xuchen, Karima Abutaleb, Jered Weinstock, Susana Gaviria, Gustavo Nino.

Resources: Xilei Xuchen, Jered Weinstock, Gustavo Nino.

Supervision: Geovanny F. Perez, Gustavo Nino.

Validation: Gustavo Nino.

Visualization: Gustavo Nino.

Writing – original draft: Geovanny F. Perez, Gustavo Nino.

Writing – review & editing: Maria Arroyo, Kyle Salka, Elizabeth Chorvinsky, Karima Abutaleb, Geovanny F. Perez, Maria J. Gutierrez, Gustavo Nino.

References

1. O’Neill L.A., Sheedy F.J. & McCoy C.E. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol 11, 163–175 (2011) https://doi.org/10.1038/nri2957 PMID: 21331081
2. Jia S, Zhai H, Zhao M. MicroRNAs regulate immune system via multiple targets. Discov Med. 2014 Nov; 18(100):237–47.
3. Vigorito E., Kohlhaas S., Lu D. & Leyland R. miR-155: an ancient regulator of the immune system. Immunol Rev 253, 146–157 (2013). https://doi.org/10.1111/imr.12057 PMID: 23550644
4. Seddiki N, Brezar V, Ruffin N, Lévy Y, Swaminathan S. Role of miR-155 in the regulation of lymphocyte immune function and disease. Immunology. 2014 May; 142(1):32–8. https://doi.org/10.1111/imm.12227 Review PMID: 24303979
5. Lu LF, Gasteiger G, Yu IS, Chaudhry A, Hsin JP, Lu Y, et al. A Single miRNA-mRNA Interaction Affects the Immune Response in a Context- and Cell-Type-Specific Manner. Immunity. 2015 Jul 21; 43(1):52–64. https://doi.org/10.1016/j.immuni.2015.04.022 Epub 2015 Jul 7. PMID: 26163372; PubMed Central PMCID: PMC4529747.

6. Hsin JP, Lu Y, Loeb GB, Leslie CS, Rudensky AY. The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types. Nat Immunol. 2018 Oct; 19(10):1137–1145. https://doi.org/10.1038/s41590-018-0208-x Epub 2018 Sep 17. PMID: 30224821; PubMed Central PMCID: PMC6158091.

7. O’Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A. 2007 Jan 30; 104(5):1604–9. Epub 2007 Jan 22. https://doi.org/10.1073/pnas.0610731104 PMID: 17242365.

8. Goncalves-Alves E, Saferding V, Schliehe C, Benson R, Kurowska-Stolarska M, Brunner JS, et al. MicroRNA-155 Controls T Helper Cell Activation During Viral Infection. Front Immunol. 2019 Jun 13; 10:1367. https://doi.org/10.3389/fimmu.2019.01367 PMID: 31275315.

9. Gracias DT, Stelekati E, Hope JL, Boesteanu AC, Doering TA, Norton J, et al. The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling. Nat Immunol. 2013 Jun; 14(6):593–602. https://doi.org/10.1038/ni.2576 Epub 2013 Apr 21. PMID: 23603793.

10. Tsai CY, Allie SR, Zhang W, Usherwood EJ. MicroRNA miR-155 affects antiviral effector and effector Memory CD8 T cell differentiation. J Virol. 2013 Feb; 87(4):2348–51. https://doi.org/10.1128/JVI.01742-12 Epub 2012 Dec 5. PMID: 23221547.

11. Bhela S, Mullik S, Reddy PB, Richardson RL, Gimenez F, Rajasagi NK, et al. Critical role of microRNA-155 in herpes simplex encephalitis. J Immunol. 2014 Mar 15; 192(6):2734–43. https://doi.org/10.4049/jimmunol.1303226 Epub 2014 Feb 10. PMID: 24516198.

12. Jiang M, Broering R, Trippler M, Wu J, Zhang E, Zhang X, et al. MicroRNA-155 controls Toll-like receptor 3- and hepatitis C virus-induced immune responses in the liver. J Viral Hepat. 2014 Feb; 21(2):99–110. https://doi.org/10.1111/jvhe.12126 Epub 2013 Sep 11. PMID: 23439323.

13. Wang P, et al. Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. J Immunol. 185, 6226–6233 (2010) https://doi.org/10.4049/jimmunol.1000491 PMID: 20937844.

14. Gutierrez MJ, Gomez JL, Perez GF, Pancham K, Val S, Pillai DK, et al. Airway Secretory microRNAome Changes during Rhinovirus Infection in Early Childhoo. PLoS One. 2016 Sep 19; 11(9):e0162244. https://doi.org/10.1371/journal.pone.0162244 eCollection 2016. PMID: 27643599.

15. Inchley CS, Sonerud T, Fjærli HO, Nakstad B. Nasal mucosal microRNA expression in children with respiratory syncytial virus infection. BMC Infect Dis. 2015 Mar 25; 15:150. https://doi.org/10.1186/s12879-015-0878-z PMID: 25884957.

16. Mann M, Mehta A, Zhao JL, Pelly VS, et al. Transcriptomics identified a critical role for TH2 cell-intrinsic miR-155 in mediating allergy and antihelminth immunity. Proc Natl Acad Sci U S A. 2014 Jul 29; 111(30):E3081–90. https://doi.org/10.1073/pnas.1406322111 Epub 2014 Jul 14. PMID: 25024218.

17. Johansson K, Malmhäll C, Ramos-Ramirez P, Rådinger M. MicroRNA-155 is a critical regulator of type 2 innate lymphoid cells and IL-33 signaling in experimental models of allergic airway inflammation. J Allergy Clin Immunol. 2017 Mar; 139(3):1007–1016.e9. https://doi.org/10.1016/j.jaci.2016.06.035 Epub 2016 Aug 1. PMID: 27492144.

18. O’Connell RM, Kahn D, Gibson WS, Round JL, Scholz RL, Chaudhuri AA, et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity. 2010 Oct 29; 33(4):607–19. https://doi.org/10.1016/j.immuni.2010.09.008 Epub 2010 Sep 30. PMID: 20888269; PubMed Central PMCID: PMC2966521.

19. Mann M, Mehta A, Zhao JL, Lee K, Marinov GK, Garcia-Flores Y, et al. An NF-κB-microRNA regulatory network tunes macrophage inflammatory responses. Nat Commun. 2017 Oct 11; 8(1):851. https://doi.org/10.1038/s41467-017-00972-z Erratum in: Nat Commun. 2018 Aug 16;9(1):3338. PMID: 29021573; PubMed Central PMCID: PMC5636846.
22. Pociask DA, Robinson KM, Chen K, McHugh KJ, Clay ME, Huang GT, et al. Epigenetic and Transcriptomic Regulation of Lung Repair during Recovery from Influenza Infection. Am J Pathol. 2017 Apr; 187(4):851–863. https://doi.org/10.1016/j.ajpath.2016.12.012 Epub 2017 Feb 10. PMID: 28193481

23. De Smet EG, Van Eeckhoute HP, Avila Cobos F, Blomme E, Verhamme FM, Provoost S, et al. The role of miR-155 in cigarette smoke-induced pulmonary inflammation and COPD. Mucosal Immunol. 2019 Dec 9. https://doi.org/10.1038/s41385-019-0241-6 PMID: 31819170

24. Perez GF, Kuri B, Megala R, Pancham K, Huseni S, Isaza N, et al. Phenotypical characterization of human rhinovirus infections in severely premature children. Pediatr Neonatol. 2018 Jun; 59(3):244–250. https://doi.org/10.1016/j.pedneo.2017.04.008 PMID: 29033350

25. Rodríguez-Martínez CE, Sossa-Briceño MP, Nino G. Predictors of prolonged length of hospital stay for infants with bronchiolitis. J Investig Med. 2018; 66(6):986–991. https://doi.org/10.1136/jim-2018-000708 PMID: 29588331

26. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003 Nov; 143(5 Suppl):S127–32. https://doi.org/10.1067/mis022-3476(03)00510-9 PMID: 14615711

27. Inagaki K, Blakesear C, Burns PA, Hobbs CV. Racial/Ethnic Disparity in the Incidence of Bronchiolitis Requiring Hospitalization. Clin Infect Dis. 2020 Feb 5. pii: ciaa113. https://doi.org/10.1093/cid/ciaa113 PMID: 32020165

28. Qiu L, Zhang Y, Do DC, Ke X, Zhang S, Lambert K, et al. miR-155 Modulates Cockroach Allergen- and Oxidative Stress-Induced Cyclooxygenase-2 in Asthma. J Immunol. 2018 Aug 1; 201(3):916–929. https://doi.org/10.4049/jimmunol.1701167 Epub 2018 Jul 2. PMID: 29967100; PubMed Central PMCID: PMC6057819.

29. Jiang K, Yang J, Guo S, Zhao G, Wu H, Deng G. Peripheral Circulating Exosome-Mediated Delivery of miR-155 as a Novel Mechanism for Acute Lung Inflammation. Mol Ther. 2019 Oct 2; 27(10):1758–1771. https://doi.org/10.1016/j.molther.2019.07.003 Epub 2019 Jul 15. PMID: 31405809

30. Yee D, Shah KM, Coles MC, Sharp TV, Lagos D. MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells. J Biol Chem. 2017 Dec 15; 292(50):20683–20693. https://doi.org/10.1074/jbc.M117.809053 Epub 2017 Oct 24. PMID: 29066622

31. Wu XY, Fan WD, Fang R, Wu GF. Regulation of microRNA-155 in endothelial inflammation by targeting nuclear factor (NF)-κB P65. J Cell Biochem. 2014 Nov; 115(11):1928–36. https://doi.org/10.1002/jcb.24664 PMID: 24905663.

32. Pullikainen KH, Ylä-Herttuala S, Levonen AL. Heme oxygenase 1 is induced by miR-155 via reduced BACH1 translation in endothelial cells. Free Radic Biol Med. 2011 Dec 1; 51(11):2124–31. https://doi.org/10.1016/j.freeradbiomed.2011.09.014 Epub 2011 Sep 17. PMID: 21982894

33. Antunes JC, Benarroch L, Moraes FC, Juenet M, Gross MS, Aubart M, et al. Core-Shell Polymer-Based Nanoparticles Deliver miR-155-5p to Endothelial Cells. Mol Ther Nucleic Acids. 2019 Sep 6; 17:210–222. https://doi.org/10.1016/j.omtn.2019.05.016 Epub 2019 Jun 4. PMID: 31265949